These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 31202122)

  • 1. Parallel imports, price controls, and innovation.
    Reisinger M; Saurí L; Zenger H
    J Health Econ; 2019 Jul; 66():163-179. PubMed ID: 31202122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The economics of parallel trade.
    Danzon PM
    Pharmacoeconomics; 1998 Mar; 13(3):293-304. PubMed ID: 10178655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pricing and welfare implications of parallel imports in the pharmaceutical industry.
    Jelovac I; Bordoy C
    Int J Health Care Finance Econ; 2005 Mar; 5(1):5-21. PubMed ID: 15714261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Price-cap Regulation, Uncertainty and the Price Evolution of New Pharmaceuticals.
    Shajarizadeh A; Hollis A
    Health Econ; 2015 Aug; 24(8):966-77. PubMed ID: 24990225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Price regulation in the pharmaceutical industry: prescription or placebo?
    Abbott TA
    J Health Econ; 1995 Dec; 14(5):551-65. PubMed ID: 10156501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaceutical patents and price controls.
    Vogel RJ
    Clin Ther; 2002 Jul; 24(7):1204-22; discussion 1202-3. PubMed ID: 12182263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. European healthcare policies for controlling drug expenditure.
    Ess SM; Schneeweiss S; Szucs TD
    Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parallel imports and the pricing of pharmaceutical products: evidence from the European Union.
    Ganslandt M; Maskus KE
    J Health Econ; 2004 Sep; 23(5):1035-57. PubMed ID: 15353192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential pricing for pharmaceuticals: reconciling access, R&D and patents.
    Danzon PM; Towse A
    Int J Health Care Finance Econ; 2003 Sep; 3(3):183-205. PubMed ID: 14625999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of parallel trade on pharmaceutical firm's profits: rise or fall?
    Guo S; Hu B; Zhong H
    Eur J Health Econ; 2013 Apr; 14(2):345-55. PubMed ID: 22286662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitigating regulatory impact: the case of partial price controls on metformin in India.
    Bhaskarabhatla A; Chatterjee C; Anurag P; Pennings E
    Health Policy Plan; 2017 Mar; 32(2):194-204. PubMed ID: 28207048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retail price regulation and innovation: reference pricing in the pharmaceutical industry.
    Bardey D; Bommier A; Jullien B
    J Health Econ; 2010 Mar; 29(2):303-16. PubMed ID: 20053474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does reimportation reduce price differences for prescription drugs? Lessons from the European Union.
    Kyle MK; Allsbrook JS; Schulman KA
    Health Serv Res; 2008 Aug; 43(4):1308-24. PubMed ID: 18355258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parallel imports and innovation in an emerging economy: the case of Indian pharmaceuticals.
    Mantovani A; Naghavi A
    Health Econ; 2012 Nov; 21(11):1286-99. PubMed ID: 23027711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eliminating innovation: how price controls limit access.
    Ingram J
    J Leg Med; 2011 Jan; 32(1):115-28. PubMed ID: 21391059
    [No Abstract]   [Full Text] [Related]  

  • 16. Parallel imports under a manufacturer rebate and a price freeze: Evidence from Germany.
    Birg L
    Health Econ; 2023 Feb; 32(2):302-323. PubMed ID: 36336829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incentives and disincentives to drug innovation: evidence from recent literature.
    Lee Mendoza R
    J Med Econ; 2019 Aug; 22(8):713-721. PubMed ID: 31038374
    [No Abstract]   [Full Text] [Related]  

  • 18. Price regulation of pharmaceuticals in Canada.
    Anis AH; Wen Q
    J Health Econ; 1998 Jan; 17(1):21-38. PubMed ID: 10176313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unsettling drug patent settlements: a framework for presumptive illegality.
    Carrier MA
    Mich Law Rev; 2009 Oct; 108(1):37-80. PubMed ID: 20535881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parallel trade of pharmaceuticals: The Danish market for statins.
    Méndez SJ
    Health Econ; 2018 Feb; 27(2):333-356. PubMed ID: 28868645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.